IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v16y2025i1d10.1038_s41467-025-59168-5.html
   My bibliography  Save this article

Remdesivir, mAb114, REGN-EB3, and ZMapp partially rescue nonhuman primates infected with a low passage Kikwit variant of Ebola virus

Author

Listed:
  • Abhishek N. Prasad

    (University of Texas Medical Branch
    University of Texas Medical Branch)

  • Courtney Woolsey

    (University of Texas Medical Branch
    University of Texas Medical Branch)

  • Viktoriya Borisevich

    (University of Texas Medical Branch
    University of Texas Medical Branch)

  • Krystle N. Agans

    (University of Texas Medical Branch
    University of Texas Medical Branch)

  • Daniel J. Deer

    (University of Texas Medical Branch
    University of Texas Medical Branch)

  • Joan B. Geisbert

    (University of Texas Medical Branch
    University of Texas Medical Branch)

  • Mack B. Harrison

    (University of Texas Medical Branch
    University of Texas Medical Branch)

  • Natalie S. Dobias

    (University of Texas Medical Branch
    University of Texas Medical Branch)

  • Karla A. Fenton

    (University of Texas Medical Branch
    University of Texas Medical Branch)

  • Robert W. Cross

    (University of Texas Medical Branch
    University of Texas Medical Branch)

  • Thomas W. Geisbert

    (University of Texas Medical Branch
    University of Texas Medical Branch)

Abstract

In 2018, a clinical trial of four investigational therapies for Ebola virus disease (EVD), known as the PALM trial, was conducted in the Democratic Republic of Congo. All patients received either the antiviral remdesivir (RDV) or a monoclonal antibody product: ZMapp, mAb114 (Ebanga), or REGN-EB3 (Inmazeb). The study concluded that both mAb114 and REGN-EB3 were superior to ZMapp and RDV in reducing mortality from EVD. However, the data suggested that some patients in the RDV and ZMapp groups might have been sicker at the time of treatment initiation. Here, we assessed the efficacy of each of these therapies in a uniformly lethal rhesus monkey model of EVD when treatment was initiated 5 days after Ebola exposure. Treatment with RDV, mAb114, REGN-EB3, and ZMapp each resulted in similar survival (approximately 40%). Survival was associated with circulating viral load at treatment initiation. A trend of more escape mutants in the GP1 and GP2 domains was observed for the mAb114 group. Our data show similar suboptimal efficacy of individual therapeutics in the uniformly lethal NHP model of EVD, supporting further clinical investigation of therapeutic combinations to maximize the overall therapeutic effect and improve patient outcomes, particularly for the treatment of advanced stage EVD.

Suggested Citation

  • Abhishek N. Prasad & Courtney Woolsey & Viktoriya Borisevich & Krystle N. Agans & Daniel J. Deer & Joan B. Geisbert & Mack B. Harrison & Natalie S. Dobias & Karla A. Fenton & Robert W. Cross & Thomas , 2025. "Remdesivir, mAb114, REGN-EB3, and ZMapp partially rescue nonhuman primates infected with a low passage Kikwit variant of Ebola virus," Nature Communications, Nature, vol. 16(1), pages 1-13, December.
  • Handle: RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-59168-5
    DOI: 10.1038/s41467-025-59168-5
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-025-59168-5
    File Function: Abstract
    Download Restriction: no

    File URL: https://libkey.io/10.1038/s41467-025-59168-5?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-59168-5. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.